Modern Pediatrics. Ukraine. (2025).6(150): 7-12. doi: 10.15574/SP.2025.6(150).712
Kushnirenko S. V.¹, Savytska L. M.¹, Tykhonenko N. O.², Markotenko O. O.²

1. Shupyk National Healthcare University of Ukraine, Kyiv
2. Kyiv City Children's Clinical Hospital No. 1, Ukraine

For citation: Kushnirenko SV, Savytska LM, Tykhonenko NO, Markotenko OO. (2025). Prospects for the use of standardized Lespedeza capitata extract in children with chronic kidney disease. Modern Pediatrics. Ukraine. 6(150): 7-12. doi: 10.15574/SP.2025.6(150).712.
Article received: Apr 16, 2025. Accepted for publication: Sep 16, 2025.

Chronic kidney disease (CKD) in children is a major clinical challenge due to its risk of progression to end-stage renal disease and resulting long-term morbidity.
Aim – to evaluate the efficacy, safety, tolerability, and nephroprotective potential of standardized Lespedeza capitata extract as an adjunct to standard therapy in children with stage 2 CKD.
Materials and methods. An open-label, single-center, prospective study enrolled 118 children aged 7-17 years (mean age 11.3±0.24) with stage 2 CKD, defined by an estimated glomerular filtration rate (eGFR) of 60-89 mL/min/1.73 m² and a morning urine albumin-to-creatinine ratio (ACR) >30 mg/g. All patients received renin-angiotensin-aldosterone system (RAAS) antagonists and standardized Lespedeza capitata extract (300 mg per capsule, three times daily with meals) for three months.
Results. After treatment, a significant reduction in ACR was observed (from 74.2±6.8 mg/g to 49.3±2.3 mg/g). Positive trends were also noted for eGFR (from 73.4±3.6 to 75.6±2.8 mL/min/1.73 m²) and serum urea (from 13.4±1.5 to 11.6±1.7 mmol/L). In patients receiving iron and erythropoiesis-stimulating agents, hemoglobin and hematocrit improved after one month (117.2±2.4 g/L and 35.3±1.7%) and further increased after three months (124.1±3.6 g/L and 37.2±1.8%). Ejection fraction rose by 16% compared with baseline.
Conclusions. Standardized Lespedeza capitata extract demonstrated good efficacy, safety, and tolerability in children with stage 2 CKD. The reduction in ACR and stable eGFR support its potential nephroprotective effect in pediatric practice.
The study complied with the principles of the Declaration of Helsinki and was approved by the institutional ethics committee. Informed consent was obtained from the patients prior to participation.
The authors declare no conflict of interest.
Keywords: chronic kidney disease, children, Lespedeza capitata, nephroprotection, estimated glomerular filtration rate, albumin/creatinine ratio.

REFERENCES

1. Beng-Ongey H, Robinson JS, Moxey-Mims M. (2022, Jun). Chronic kidney disease emerging trends in children and what to do about it. J Natl Med Assoc. 114(3S2): S50-S55. Epub 2022 May 31. https://doi.org/10.1016/j.jnma.2022.05.002; PMid:35660045

2. Beus JM, Liu K, Westbrook A, Harding JL, Orenstein EW, Shin HS et al. (2025, Mar 4). Incidence of Leading Causes of Pediatric CKD Using Electronic Health Record-Driven Computable Phenotype. Kidney360. 6(7): 1096-1105. https://doi.org/10.34067/KID.0000000753; PMid:40036078 PMCid:PMC12338353

3. Cirillo L, De Chiara L, Innocenti S et al. (2023). Chronic kidney disease in children: an update. Clin Kidney J. 16(10):1600-1611. https://doi.org/10.1093/ckj/sfad097; PMid:37779846 PMCid:PMC10539214

4. Corsello A, Trovato CM, Dipasquale V et al. (2025). Malnutrition management in children with chronic kidney disease. Pediatr Nephrol. 40: 15-24. https://doi.org/10.1007/s00467-024-06436-z; PMid:38954039 PMCid:PMC11584524

5. Deng YH, Liu Q, Luo XQ. (2025). From acute kidney injury to chronic kidney disease in children: maladaptive repair and the need for long-term surveillance – a literature review. BMC Nephrol. 26: 449. https://doi.org/10.1186/s12882-025-04392-w; PMid:40790474 PMCid:PMC12337562

6. Gerber A, Kamath N. (2025, Mar-Apr). Not Just Small Adults: Considerations for Pediatric Chronic Kidney Disease. Indian J Nephrol. 35(2): 168-177. Epub 2024 Jul 1. https://doi.org/10.25259/IJN_77_2024; PMid:40060064 PMCid:PMC11883310

7. Geylis M, Coreanu T, Novack V, Landau D. (2023). Risk factors for childhood chronic kidney disease: a population-based study. Pediatr Nephrol. 38: 1569-1576. https://doi.org/10.1007/s00467-022-05714-y; PMid:36018434

8. Harada R, Hamasaki Y, Okuda Y, Hamada R, Ishikura K (2022). Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies. Pediatr Nephrol. 37: 1215-1229. https://doi.org/10.1007/s00467-021-05145-1; PMid:34091754

9. Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. (2012) Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 27: 363-373. https://doi.org/10.1007/s00467-011-1939-1; PMid:21713524 PMCid:PMC3264851

10. Hedin E, Tungsanga S, Ye F et al. (2025). Global prevalence of chronic kidney disease and associated risk factors in children and adolescents: protocol for a systematic review and meta-analysis. BMJ Open. 15: e090615. https://doi.org/10.1136/bmjopen-2024-090615; PMid:40523794 PMCid:PMC12314819

11. Hsu C-N, Lu P-C, Liao W-T, Tain Y-L. (2025). Pediatric Chronic Kidney Disease: Mind the Gap Between Reality and Expectations. Children. 12(5): 614. https://doi.org/10.3390/children12050614; PMid:40426793 PMCid:PMC12110040

12. National Kidney Foundation. (2002). K/DOQI clinical practice guidelines for chronic kidney diseases: evaluation, classification and stratification. Am. J. Kidney Dis. 39; suppl. 1: S17-S31.

13. KDIGO. (2024). Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024.

14. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. (2012). KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter. Suppl. 2: 279-335.

15. Kidney Disease: Improving Global Outcomes (KDIGO) СKD Work Group. (2013). KDIGO (2012). Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter. Suppl. 3: 1-150.

16. Lee JH, Seo J, Lee CH, Jeong CW, Kwak C, Kim HH et al. (2021). Protective effect of isoorientin against cisplatin-induced kidney injury via SIRT1 and Nrf2 pathway activation. Pharmaceutics. 13(12): 2116. https://doi.org/10.3390/pharmaceutics13122116; PMid:34959397 PMCid:PMC8708448

17. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC et al. (2019). Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol. 74(14): 1823-1838. https://doi.org/10.1016/j.jacc.2019.08.1017; PMid:31582143

18. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F et al. (2009). New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 20(3): 629-637. https://doi.org/10.1681/ASN.2008030287; PMid:19158356 PMCid:PMC2653687

19. Stern-Zimmer M, Calderon-Margalit R, Skorecki K, Vivante A. (2021). Childhood risk factors for adulthood chronic kidney disease. Pediatr Nephrol. 36: 1387-1396. https://doi.org/10.1007/s00467-020-04611-6; PMid:32500249

20. Waith FM, Bresolin NL, Antwi S. (2025). Detect early, protect kidney health: World Kidney Day 2025. Pediatr Nephrol. 40: 1511-1514. https://doi.org/10.1007/s00467-025-06714-4; PMid:39960639

21. Zhang D, Liu H, Liu W, Wang J, He Y, Xu D. (2021). Lespedeza bicolor ameliorates diabetic nephropathy by inhibiting inflammation via the NF-κB pathway. J Ethnopharmacol. 268: 113605. https://doi.org/10.1016/j.jep.2020.113605; PMid:33232779